Codagenix starts phase I trial for COVID-19 vaccine in U.K.

By The Science Advisory Board staff writers

January 11, 2021 -- The first patient has been dosed in a phase I clinical trial being conducted by Codagenix and the Serum Institute of India of COVI-VAC, a single-dose, intranasal vaccine against the SARS-CoV-2 virus.

Codagenix and the Serum Institute of India announced the start of the phase I trial in December following regulatory approval from the U.K. Medicines and Healthcare Products Regulatory Agency. It is operating as a randomized, double-blinded, placebo-controlled dose-escalation study among 48 volunteers.

Open Orphan subsidiary hVIVO is conducting the study, which will evaluate COVI-VAC's safety and tolerability as well as its ability to provoke an immune response. The formulation has the advantage of only requiring a single dose and not needing a needle, syringe, or ultra-low-temperature storage.

Codagenix intends to report initial data by the middle of this year, with plans to begin advanced clinical testing soon after.

Clinical trial of intranasal live-attenuated COVID-19 vaccine begins in U.K.
Codagenix and the Serum Institute of India have begun a phase I clinical trial of COVI-VAC in London after receiving regulatory approval from the Medicines...
Serum Institute to make Codagenix's COVID-19 vaccine
Serum Institute of India has begun manufacturing Codagenix's COVID-19 vaccine candidate, CDX-005.
Codagenix synthesizes live-attenuated COVID-19 vaccine
Codagenix has successfully synthesized a live-attenuated vaccine candidate for COVID-19 called CDX-005.
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Copyright © 2021 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter